Two years ago, Flemming Ørnskov took up a new challenge as CEO of Galderma with the expectation he would work the magic like he did with Shire — culminating in the rare disease biotech’s $62 billion sale to Takeda — with the pure-play dermatology outfit freshly spun out of Nestlé.
According to FDA’s briefing documents released ahead of the meeting, maribavir proved safe across multiple studies and statistically superior to investigator-assigned treatment (IAT) in a Phase III trial, which Takeda announced earlier this year.
Delix Therapeutics, named a 2021 Fierce 15 winner today, has secured $70 million to bring two psychedelic analogs through phase 1 trials to treat brain disorders and boost its drug discovery work.
A week before the FDA is set to decide on Mirum Pharmaceuticals’ lead liver disease drug — an old Shire cast-off called maralixibat — Takeda is swooping in to secure the rights in Japan.
AbbVie dodges hedge fund lawsuit over failed $55B Shire pursuit
Takeda has already exceeded the product sell-off goal it set alongside its Shire merger, but the Japanese pharma shows no sign of slowing down.
The Takeda sell-off may be nearing completion.
Japan’s biggest drug firm Takeda is said to be mulling plans to cut back its sales operations with a new restructuring programme as part of its ongoing plan to jettison around $10 billion in non-core assets in the wake of its titanic $59 billion acquisition of rare disease firm Shire that completed last year.
Takeda has been burdened under mountains of debt since acquiring Shire for $62 billion 18 months ago, but one of the company’s biggest moves yet to relieve the stress could be on the horizon.
Novartis last year bought Shire’s dry eye drug Xiidra from Takeda to beef up its ophthalmic offerings and reap blockbuster sales along the way. But now, the $3 billion-plus buy doesn't look so appealing.